Shandong Xinhua Pharmaceutical Co Ltd (000756) - Total Liabilities
Based on the latest financial reports, Shandong Xinhua Pharmaceutical Co Ltd (000756) has total liabilities worth CN¥3.87 Billion CNY (≈ $566.69 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 000756 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Shandong Xinhua Pharmaceutical Co Ltd - Total Liabilities Trend (2015–2024)
This chart illustrates how Shandong Xinhua Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 000756 total assets.
Shandong Xinhua Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shandong Xinhua Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FAWER Automotive Parts Ltd Co
SHE:000030
|
China | CN¥9.40 Billion |
|
Shandong Bohui Paper Industry Co Ltd
SHG:600966
|
China | CN¥17.07 Billion |
|
Tyntek Corp
TW:2426
|
Taiwan | NT$972.75 Million |
|
CHERVON HOLDINGS LTD
F:AZ9
|
Germany | €826.08 Million |
|
Guangxi Wuzhou Communications Co Ltd
SHG:600368
|
China | CN¥4.63 Billion |
|
ArcherMind Technology Nanjing Co Ltd
SHE:300598
|
China | CN¥1.26 Billion |
|
Wereldhave NV
AS:WHA
|
Netherlands | €1.30 Billion |
|
Metalurgica Gerdau S.A
SA:GOAU3
|
Brazil | R$28.24 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down Shandong Xinhua Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Shandong Xinhua Pharmaceutical Co Ltd net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.76 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shandong Xinhua Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shandong Xinhua Pharmaceutical Co Ltd (2015–2024)
The table below shows the annual total liabilities of Shandong Xinhua Pharmaceutical Co Ltd from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥3.80 Billion ≈ $556.37 Million |
+8.31% |
| 2023-12-31 | CN¥3.51 Billion ≈ $513.68 Million |
-10.34% |
| 2022-12-31 | CN¥3.92 Billion ≈ $572.92 Million |
+6.37% |
| 2021-12-31 | CN¥3.68 Billion ≈ $538.63 Million |
-0.56% |
| 2020-12-31 | CN¥3.70 Billion ≈ $541.67 Million |
+11.31% |
| 2019-12-31 | CN¥3.33 Billion ≈ $486.62 Million |
+6.60% |
| 2018-12-31 | CN¥3.12 Billion ≈ $456.50 Million |
+15.79% |
| 2017-12-31 | CN¥2.69 Billion ≈ $394.25 Million |
+1.92% |
| 2016-12-31 | CN¥2.64 Billion ≈ $386.82 Million |
+5.40% |
| 2015-12-31 | CN¥2.51 Billion ≈ $367.01 Million |
-- |
About Shandong Xinhua Pharmaceutical Co Ltd
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. It offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for act… Read more